RT Journal Article
SR Electronic
T1 CGRP antagonists for decreasing migraine frequency: New options, long overdue
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 211
OP 218
DO 10.3949/ccjm.87a.19048
VO 87
IS 4
A1 Julia Bucklan
A1 Zubair Ahmed
YR 2020
UL http://www.ccjm.org/content/87/4/211.abstract
AB The cornerstone of preventive migraine treatment has long been drugs developed for other diseases such as epilepsy, depression, and hypertension. But a new set of drugs is available for preventing migraine attacks: erenumab, galcanezumab, fremanezumab, and eptinezumab. These monoclonal antibodies target calcitonin gene-related peptide (CGRP) or its receptors, each a key molecule in the pathophysiology of migraine.